# This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

> **NCT06853223** · PHASE2 · RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 120 (estimated)

## Conditions studied

- Primary Graft Dysfunction
- Lung Transplantation
- Acute Lung Injury(ALI)
- Natural Killer Cell Mediated Immunity

## Interventions

- **DRUG:** Maraviroc
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06853223
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-07
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-08-14
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06853223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06853223, "This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06853223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*